Contact Us | Print Page | Sign In | Register
The Science of MS Management: Using Science to Select MS Therapies
Share |
Using Science to Select MS Therapies

The Science of MS Management: Using Science to Select MS Therapies
Corey C. Ford, MD, PhD; James D. Bowen, MD; Lael Stone, MD
CME/CE Released: 12/2/2011; Credit validation expired on 12/1/2012
Faculty and Disclosures
Corey C. Ford, MD, PhD, Chair
Dr. Ford has disclosed the following financial relationships:
Consulting fees: Biogen Idec, EMD Serono, Novartis, Teva Neuroscience
Contracted research: Biogen Idec, Elan, EMD Serono, Genentech, Genzyme, Janssen, Novartis, Ono Pharmaceutical, Roche, Sanofi-Aventis, Teva Neuroscience

James D. Bowen, MD

James Bowen has disclosed the following financial relationships:
Fees for non-CME services: Acorda Therapeutics, Bayer HealthCare, Biogen Idec, EMD Serono, Novartis, Pfizer, and Teva Neuroscience
Sources of funding for research: Acorda Therapeutics, Bio MS, Biogen Idec, Celgene, DioGenix, EMD Serono, Genzyme, Novartis, Sanofi-Aventis, and UCB Inc.
Stock ownership: Amgen

Lael A. Stone, MD

Lael Stone has no conflicts of interest to disclose.

Planners and Managers

The following planners and managers have no conflicts of interest to disclose: Joseph J. D'Onofrio, Frank Marino, Nancy Monson, Katherine Wandersee.
Target Audience
This publication is targeted to neurologists who have an interest in treating multiple sclerosis (MS).
Learning Objectives
Upon completion of this educational activity, the participant should be able to:
  • Outline the importance of assessing individual response to disease-modifying therapy (DMT) in multiple sclerosis (MS).
  • Analyze potential causes of treatment failure from DMTs and utilize best practice guidelines for switching to alternative therapies for your patients with MS.
  • Explain the principles of escalation, induction, and combination therapy approaches in MS in order to determine when these strategies are appropriate for a given clinical scenario.
  • Examine the theoretical role of biomarkers and genetic testing in MS in order to allow clinicians to individually tailor therapy.
Disclosure of Non-endorsement of Products
Approval does not imply endorsement by the CMSC or ACCME of any commercial products discussed in conjunction with an educational activity.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA. The CMSC, Teva Neuroscience, and Delaware Media Group do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the CMSC, Teva Neuroscience, or Delaware Media Group.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any medications, diagnostic procedures, or treatments discussed in this publication should not be used by clinicians or other health care professionals without first evaluating their patients' conditions, considering possible contraindications or risks, reviewing any applicable manufacturer's product information, and comparing any therapeutic approach with the recommendations of other authorities.
Other Information

Jointly sponsored by the Consortium of Multiple Sclerosis Centers and Delaware Media Group.

This continuing education publication is supported by an educational grant from Teva Neuroscience.

For questions relating to CME, please contact the CMSC at (201) 487-1050 or email

Link to the Program
Agree Button

The Consortium of Multiple Sclerosis Centers

3 University Plaza Drive, Suite 116 Hackensack, NJ 07601

Tel: 201.487.1050 | Fax: 862.772.7275